Concepts (300)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Low Back Pain | 12 | 2020 | 34 | 3.350 |
Why?
|
| Analgesics, Opioid | 14 | 2022 | 219 | 2.110 |
Why?
|
| Pain, Postoperative | 10 | 2019 | 177 | 2.000 |
Why?
|
| Autonomic Nerve Block | 3 | 2015 | 10 | 1.640 |
Why?
|
| Pain Measurement | 18 | 2020 | 365 | 1.370 |
Why?
|
| Analgesics | 9 | 2018 | 126 | 1.220 |
Why?
|
| Perioperative Care | 3 | 2019 | 58 | 1.180 |
Why?
|
| Sacroiliac Joint | 3 | 2014 | 9 | 1.090 |
Why?
|
| Midazolam | 2 | 2014 | 12 | 1.080 |
Why?
|
| Diagnostic Techniques and Procedures | 2 | 2014 | 7 | 1.070 |
Why?
|
| Conscious Sedation | 2 | 2014 | 22 | 1.070 |
Why?
|
| Anesthetics, Intravenous | 2 | 2014 | 18 | 1.070 |
Why?
|
| Fentanyl | 2 | 2014 | 32 | 1.060 |
Why?
|
| Complex Regional Pain Syndromes | 2 | 2014 | 20 | 1.050 |
Why?
|
| Primary Health Care | 6 | 2022 | 148 | 1.040 |
Why?
|
| Patient Satisfaction | 2 | 2016 | 218 | 1.010 |
Why?
|
| Pain | 7 | 2012 | 262 | 0.970 |
Why?
|
| Obesity | 5 | 2014 | 1067 | 0.970 |
Why?
|
| gamma-Aminobutyric Acid | 4 | 2008 | 73 | 0.940 |
Why?
|
| Humans | 57 | 2022 | 28451 | 0.880 |
Why?
|
| Opioid-Related Disorders | 6 | 2019 | 39 | 0.860 |
Why?
|
| Electronic Health Records | 3 | 2019 | 119 | 0.840 |
Why?
|
| Fear | 3 | 2014 | 33 | 0.750 |
Why?
|
| Buprenorphine | 1 | 2019 | 18 | 0.740 |
Why?
|
| Zygapophyseal Joint | 2 | 2007 | 2 | 0.680 |
Why?
|
| Resistance Training | 2 | 2014 | 68 | 0.640 |
Why?
|
| Neuralgia | 2 | 2015 | 48 | 0.620 |
Why?
|
| Cyclohexanecarboxylic Acids | 3 | 2006 | 20 | 0.620 |
Why?
|
| Amines | 3 | 2006 | 22 | 0.620 |
Why?
|
| Anesthetics, Local | 3 | 2015 | 94 | 0.610 |
Why?
|
| Male | 37 | 2020 | 17995 | 0.610 |
Why?
|
| Denervation | 4 | 2008 | 13 | 0.590 |
Why?
|
| Practice Guidelines as Topic | 3 | 2020 | 376 | 0.580 |
Why?
|
| Treatment Outcome | 14 | 2019 | 3025 | 0.580 |
Why?
|
| Stellate Ganglion | 1 | 2015 | 2 | 0.570 |
Why?
|
| Ventricular Fibrillation | 1 | 2015 | 4 | 0.570 |
Why?
|
| Medulla Oblongata | 5 | 2007 | 55 | 0.560 |
Why?
|
| Disability Evaluation | 3 | 2014 | 223 | 0.550 |
Why?
|
| Phantom Limb | 1 | 2014 | 4 | 0.540 |
Why?
|
| Receptors, Opioid, mu | 4 | 2007 | 50 | 0.530 |
Why?
|
| Receptors, Opioid, delta | 5 | 2007 | 17 | 0.520 |
Why?
|
| Health Knowledge, Attitudes, Practice | 2 | 2015 | 326 | 0.510 |
Why?
|
| Middle Aged | 21 | 2019 | 11102 | 0.510 |
Why?
|
| Schools, Medical | 1 | 2014 | 47 | 0.510 |
Why?
|
| Exercise Therapy | 2 | 2014 | 207 | 0.500 |
Why?
|
| Anesthesiology | 1 | 2014 | 47 | 0.480 |
Why?
|
| Diabetic Neuropathies | 2 | 2013 | 26 | 0.480 |
Why?
|
| Faculty, Medical | 1 | 2014 | 76 | 0.480 |
Why?
|
| Delivery of Health Care | 1 | 2014 | 126 | 0.460 |
Why?
|
| Nociceptors | 6 | 2004 | 40 | 0.450 |
Why?
|
| Spinal Cord | 4 | 2004 | 127 | 0.450 |
Why?
|
| Health Behavior | 1 | 2013 | 227 | 0.440 |
Why?
|
| Osteoarthritis | 1 | 2012 | 65 | 0.440 |
Why?
|
| Female | 26 | 2020 | 18228 | 0.440 |
Why?
|
| Postoperative Care | 3 | 2019 | 70 | 0.430 |
Why?
|
| Decision Support Systems, Clinical | 2 | 2022 | 19 | 0.410 |
Why?
|
| Adult | 14 | 2020 | 8519 | 0.400 |
Why?
|
| Walking | 4 | 2014 | 168 | 0.390 |
Why?
|
| Anemia, Sickle Cell | 2 | 2020 | 40 | 0.390 |
Why?
|
| Catheter Ablation | 2 | 2008 | 61 | 0.380 |
Why?
|
| Randomized Controlled Trials as Topic | 4 | 2017 | 451 | 0.370 |
Why?
|
| Societies, Medical | 3 | 2018 | 150 | 0.360 |
Why?
|
| Pain Threshold | 2 | 2008 | 94 | 0.360 |
Why?
|
| Ketamine | 2 | 2018 | 22 | 0.350 |
Why?
|
| Aged | 14 | 2018 | 9561 | 0.350 |
Why?
|
| Hyperalgesia | 4 | 2007 | 85 | 0.340 |
Why?
|
| Inflammation | 4 | 2007 | 497 | 0.340 |
Why?
|
| Patient Selection | 2 | 2022 | 261 | 0.340 |
Why?
|
| Spinal Diseases | 1 | 2007 | 21 | 0.340 |
Why?
|
| Enkephalin, Ala(2)-MePhe(4)-Gly(5)- | 3 | 2007 | 18 | 0.340 |
Why?
|
| Cervical Vertebrae | 1 | 2007 | 34 | 0.330 |
Why?
|
| Risk Factors | 9 | 2019 | 3527 | 0.330 |
Why?
|
| Orthopedic Procedures | 1 | 2007 | 53 | 0.330 |
Why?
|
| United States | 7 | 2020 | 3609 | 0.310 |
Why?
|
| Oligopeptides | 4 | 2007 | 55 | 0.310 |
Why?
|
| Ganglia, Spinal | 2 | 2006 | 63 | 0.310 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 2 | 2007 | 68 | 0.310 |
Why?
|
| Decision Support Techniques | 2 | 2018 | 98 | 0.300 |
Why?
|
| Analgesia | 2 | 2016 | 32 | 0.290 |
Why?
|
| Aged, 80 and over | 8 | 2016 | 3691 | 0.290 |
Why?
|
| Physical Endurance | 3 | 2013 | 37 | 0.280 |
Why?
|
| Rats, Sprague-Dawley | 9 | 2007 | 801 | 0.270 |
Why?
|
| Gait | 3 | 2014 | 90 | 0.270 |
Why?
|
| Enkephalins | 2 | 2001 | 7 | 0.260 |
Why?
|
| Postural Balance | 1 | 2016 | 120 | 0.260 |
Why?
|
| Radiosurgery | 1 | 2007 | 319 | 0.260 |
Why?
|
| Nerve Block | 3 | 2012 | 67 | 0.260 |
Why?
|
| Efferent Pathways | 1 | 2003 | 8 | 0.250 |
Why?
|
| Brain | 3 | 2019 | 955 | 0.240 |
Why?
|
| Naproxen | 1 | 2002 | 8 | 0.240 |
Why?
|
| Acetates | 1 | 2002 | 15 | 0.240 |
Why?
|
| Injections, Spinal | 3 | 2016 | 114 | 0.240 |
Why?
|
| Algorithms | 2 | 2017 | 452 | 0.240 |
Why?
|
| Research Design | 2 | 2017 | 277 | 0.240 |
Why?
|
| Pesticides | 1 | 2016 | 237 | 0.240 |
Why?
|
| Rats | 9 | 2007 | 1699 | 0.240 |
Why?
|
| Receptors, Opioid | 1 | 2003 | 37 | 0.230 |
Why?
|
| Occupational Exposure | 1 | 2016 | 285 | 0.230 |
Why?
|
| Emigrants and Immigrants | 1 | 2016 | 272 | 0.230 |
Why?
|
| Consensus | 5 | 2019 | 60 | 0.230 |
Why?
|
| Muscle Strength | 2 | 2013 | 129 | 0.230 |
Why?
|
| Neurons | 2 | 2003 | 397 | 0.220 |
Why?
|
| Transients and Migrants | 1 | 2016 | 375 | 0.220 |
Why?
|
| Anesthesia, Conduction | 2 | 2018 | 29 | 0.220 |
Why?
|
| Hematology | 1 | 2020 | 5 | 0.210 |
Why?
|
| Predictive Value of Tests | 3 | 2013 | 778 | 0.200 |
Why?
|
| Lower Extremity | 1 | 2020 | 73 | 0.200 |
Why?
|
| Animals | 12 | 2010 | 7456 | 0.190 |
Why?
|
| Periaqueductal Gray | 1 | 2019 | 2 | 0.190 |
Why?
|
| Body Mass Index | 3 | 2013 | 874 | 0.190 |
Why?
|
| User-Computer Interface | 1 | 2019 | 34 | 0.190 |
Why?
|
| Hispanic Americans | 1 | 2016 | 1093 | 0.170 |
Why?
|
| Analgesics, Non-Narcotic | 1 | 2017 | 16 | 0.170 |
Why?
|
| Classification | 1 | 2017 | 1 | 0.170 |
Why?
|
| Microinjections | 4 | 2001 | 34 | 0.160 |
Why?
|
| Medical History Taking | 1 | 2017 | 35 | 0.160 |
Why?
|
| Analgesia, Epidural | 2 | 2010 | 46 | 0.160 |
Why?
|
| Medical Informatics | 1 | 2016 | 20 | 0.160 |
Why?
|
| Cluster Analysis | 1 | 2016 | 123 | 0.150 |
Why?
|
| Ambulatory Care Facilities | 1 | 2016 | 53 | 0.150 |
Why?
|
| Lumbar Vertebrae | 2 | 2007 | 95 | 0.150 |
Why?
|
| Cross-Over Studies | 2 | 2014 | 88 | 0.150 |
Why?
|
| Placebos | 1 | 2015 | 66 | 0.150 |
Why?
|
| Organizational Case Studies | 1 | 2015 | 10 | 0.150 |
Why?
|
| Quality Assurance, Health Care | 1 | 2016 | 61 | 0.140 |
Why?
|
| Neurosurgical Procedures | 1 | 2016 | 90 | 0.140 |
Why?
|
| Evidence-Based Medicine | 4 | 2020 | 202 | 0.140 |
Why?
|
| Electric Countershock | 1 | 2015 | 10 | 0.140 |
Why?
|
| Sympathectomy | 1 | 2015 | 14 | 0.140 |
Why?
|
| Volleyball | 1 | 2015 | 1 | 0.140 |
Why?
|
| Retrospective Studies | 5 | 2015 | 2921 | 0.140 |
Why?
|
| Family Practice | 1 | 2015 | 43 | 0.140 |
Why?
|
| Young Adult | 3 | 2019 | 2372 | 0.140 |
Why?
|
| Terminology as Topic | 3 | 2019 | 65 | 0.140 |
Why?
|
| Baseball | 1 | 2015 | 12 | 0.140 |
Why?
|
| Drug Synergism | 4 | 2007 | 66 | 0.140 |
Why?
|
| Soccer | 1 | 2015 | 13 | 0.140 |
Why?
|
| Receptors, Opioid, kappa | 2 | 2008 | 40 | 0.140 |
Why?
|
| Qualitative Research | 3 | 2020 | 133 | 0.140 |
Why?
|
| Drug Administration Schedule | 3 | 2019 | 259 | 0.130 |
Why?
|
| Brain Concussion | 1 | 2015 | 53 | 0.130 |
Why?
|
| Overweight | 2 | 2013 | 256 | 0.130 |
Why?
|
| Injections, Intra-Articular | 1 | 2014 | 7 | 0.130 |
Why?
|
| Spinal Nerves | 1 | 2015 | 66 | 0.130 |
Why?
|
| False Positive Reactions | 1 | 2014 | 23 | 0.130 |
Why?
|
| Efficiency | 1 | 2014 | 15 | 0.130 |
Why?
|
| Joints | 1 | 2013 | 7 | 0.130 |
Why?
|
| Neuralgia, Postherpetic | 1 | 2013 | 5 | 0.130 |
Why?
|
| Patient Education as Topic | 1 | 2015 | 227 | 0.130 |
Why?
|
| Neurotoxicity Syndromes | 1 | 2013 | 19 | 0.130 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2015 | 155 | 0.130 |
Why?
|
| Cost of Illness | 1 | 2013 | 60 | 0.130 |
Why?
|
| Health Policy | 1 | 2014 | 72 | 0.130 |
Why?
|
| Affect | 1 | 2013 | 59 | 0.120 |
Why?
|
| Phobic Disorders | 1 | 2013 | 8 | 0.120 |
Why?
|
| Peripheral Nervous System Diseases | 1 | 2013 | 40 | 0.120 |
Why?
|
| Chronic Disease | 3 | 2013 | 372 | 0.120 |
Why?
|
| Time Factors | 5 | 2019 | 2000 | 0.120 |
Why?
|
| Health Care Surveys | 1 | 2014 | 180 | 0.120 |
Why?
|
| Patient Care Team | 1 | 2013 | 122 | 0.120 |
Why?
|
| Adaptation, Psychological | 1 | 2013 | 125 | 0.120 |
Why?
|
| Celiac Plexus | 1 | 2012 | 3 | 0.120 |
Why?
|
| Databases, Factual | 1 | 2014 | 328 | 0.120 |
Why?
|
| Risk Assessment | 4 | 2019 | 1299 | 0.110 |
Why?
|
| Combined Modality Therapy | 1 | 2013 | 532 | 0.110 |
Why?
|
| Incidence | 3 | 2019 | 1072 | 0.110 |
Why?
|
| Mobility Limitation | 1 | 2013 | 181 | 0.110 |
Why?
|
| Adolescent | 4 | 2019 | 3127 | 0.110 |
Why?
|
| Behavior, Addictive | 1 | 2010 | 28 | 0.100 |
Why?
|
| Pancreatic Neoplasms | 1 | 2012 | 129 | 0.100 |
Why?
|
| Checklist | 1 | 2010 | 35 | 0.100 |
Why?
|
| HIV Infections | 1 | 2013 | 253 | 0.100 |
Why?
|
| Diet | 1 | 2012 | 342 | 0.100 |
Why?
|
| Delphi Technique | 2 | 2019 | 30 | 0.100 |
Why?
|
| Epidural Space | 1 | 2009 | 7 | 0.090 |
Why?
|
| Muscle, Skeletal | 1 | 2013 | 487 | 0.090 |
Why?
|
| Steroids | 1 | 2009 | 36 | 0.090 |
Why?
|
| Regression Analysis | 3 | 2013 | 291 | 0.090 |
Why?
|
| Infusions, Intravenous | 2 | 2018 | 88 | 0.090 |
Why?
|
| Magnetic Resonance Imaging | 2 | 2019 | 1194 | 0.090 |
Why?
|
| Neck Pain | 1 | 2007 | 6 | 0.090 |
Why?
|
| Radiculopathy | 1 | 2007 | 4 | 0.080 |
Why?
|
| Models, Statistical | 1 | 2008 | 158 | 0.080 |
Why?
|
| Receptors, Tumor Necrosis Factor | 1 | 2007 | 43 | 0.080 |
Why?
|
| Hindlimb | 3 | 2007 | 57 | 0.080 |
Why?
|
| Sex Characteristics | 1 | 2008 | 172 | 0.080 |
Why?
|
| Data Interpretation, Statistical | 1 | 2007 | 106 | 0.080 |
Why?
|
| Positron-Emission Tomography | 1 | 2008 | 170 | 0.080 |
Why?
|
| Forecasting | 1 | 2007 | 133 | 0.080 |
Why?
|
| Immunoglobulin G | 1 | 2007 | 103 | 0.080 |
Why?
|
| Nortriptyline | 1 | 2006 | 3 | 0.080 |
Why?
|
| Carbamazepine | 1 | 2006 | 4 | 0.080 |
Why?
|
| Thoracotomy | 1 | 2006 | 19 | 0.080 |
Why?
|
| Reaction Time | 2 | 2007 | 120 | 0.080 |
Why?
|
| Fluoroscopy | 1 | 2006 | 35 | 0.080 |
Why?
|
| Dose-Response Relationship, Drug | 3 | 2007 | 656 | 0.080 |
Why?
|
| Anticonvulsants | 1 | 2006 | 52 | 0.080 |
Why?
|
| Mastectomy | 1 | 2006 | 64 | 0.070 |
Why?
|
| Adrenergic alpha-Antagonists | 2 | 2003 | 22 | 0.070 |
Why?
|
| Prevalence | 1 | 2008 | 901 | 0.070 |
Why?
|
| Disease Models, Animal | 1 | 2008 | 1021 | 0.070 |
Why?
|
| Surgical Procedures, Operative | 1 | 2004 | 72 | 0.060 |
Why?
|
| Calcium | 2 | 2002 | 304 | 0.060 |
Why?
|
| Medicare | 1 | 2004 | 172 | 0.060 |
Why?
|
| Case-Control Studies | 1 | 2016 | 917 | 0.060 |
Why?
|
| Receptors, GABA | 1 | 2003 | 6 | 0.060 |
Why?
|
| Serotonin Antagonists | 1 | 2003 | 5 | 0.060 |
Why?
|
| GABA Antagonists | 1 | 2003 | 12 | 0.060 |
Why?
|
| Receptors, Serotonin | 1 | 2003 | 6 | 0.060 |
Why?
|
| Narcotics | 1 | 2003 | 19 | 0.060 |
Why?
|
| Drug Interactions | 1 | 2003 | 84 | 0.060 |
Why?
|
| Quality of Life | 1 | 2008 | 843 | 0.060 |
Why?
|
| Electronics | 1 | 2022 | 7 | 0.060 |
Why?
|
| Exercise Test | 2 | 2013 | 195 | 0.060 |
Why?
|
| Calcium Channels | 1 | 2002 | 53 | 0.060 |
Why?
|
| Research Subjects | 1 | 2022 | 28 | 0.060 |
Why?
|
| HIV Envelope Protein gp120 | 1 | 2001 | 4 | 0.060 |
Why?
|
| Patient-Centered Care | 1 | 2022 | 64 | 0.060 |
Why?
|
| Chemokines | 1 | 2001 | 34 | 0.050 |
Why?
|
| Benzeneacetamides | 1 | 2001 | 3 | 0.050 |
Why?
|
| Pyrrolidines | 1 | 2001 | 14 | 0.050 |
Why?
|
| Somatostatin | 1 | 2001 | 10 | 0.050 |
Why?
|
| Reproducibility of Results | 2 | 2016 | 705 | 0.050 |
Why?
|
| Naltrexone | 1 | 2001 | 38 | 0.050 |
Why?
|
| Indiana | 1 | 2020 | 4 | 0.050 |
Why?
|
| North Carolina | 1 | 2016 | 1642 | 0.050 |
Why?
|
| Peptides | 1 | 2001 | 110 | 0.050 |
Why?
|
| Skin Temperature | 1 | 2000 | 13 | 0.050 |
Why?
|
| Child | 2 | 2020 | 2007 | 0.050 |
Why?
|
| Receptors, Adrenergic, alpha-2 | 1 | 1999 | 29 | 0.050 |
Why?
|
| Age Factors | 2 | 2013 | 1123 | 0.050 |
Why?
|
| Enkephalin, D-Penicillamine (2,5)- | 1 | 1999 | 5 | 0.050 |
Why?
|
| Norepinephrine | 1 | 1999 | 69 | 0.050 |
Why?
|
| Rest | 1 | 2019 | 50 | 0.050 |
Why?
|
| Neural Pathways | 1 | 2019 | 98 | 0.050 |
Why?
|
| Cohort Studies | 2 | 2013 | 1662 | 0.050 |
Why?
|
| Logistic Models | 2 | 2015 | 745 | 0.040 |
Why?
|
| Brain Mapping | 1 | 2019 | 182 | 0.040 |
Why?
|
| Pilot Projects | 2 | 2012 | 462 | 0.040 |
Why?
|
| Medication Adherence | 1 | 2020 | 137 | 0.040 |
Why?
|
| Nerve Net | 1 | 2019 | 116 | 0.040 |
Why?
|
| Syndrome | 1 | 2017 | 64 | 0.040 |
Why?
|
| Quality of Health Care | 1 | 2018 | 140 | 0.040 |
Why?
|
| Prospective Studies | 2 | 2016 | 1951 | 0.040 |
Why?
|
| Public-Private Sector Partnerships | 1 | 2017 | 3 | 0.040 |
Why?
|
| Peptide Fragments | 1 | 2001 | 492 | 0.040 |
Why?
|
| Decision Making | 1 | 2018 | 173 | 0.040 |
Why?
|
| Clinical Protocols | 1 | 2016 | 87 | 0.040 |
Why?
|
| Decision Trees | 1 | 2015 | 22 | 0.040 |
Why?
|
| Random Allocation | 1 | 2015 | 217 | 0.040 |
Why?
|
| ROC Curve | 1 | 2015 | 152 | 0.030 |
Why?
|
| Sports | 1 | 2015 | 17 | 0.030 |
Why?
|
| Cross-Sectional Studies | 1 | 2018 | 1325 | 0.030 |
Why?
|
| Clinical Trials as Topic | 1 | 2016 | 312 | 0.030 |
Why?
|
| Physician-Patient Relations | 1 | 2015 | 178 | 0.030 |
Why?
|
| Self Concept | 1 | 2013 | 40 | 0.030 |
Why?
|
| Obesity, Morbid | 1 | 2013 | 54 | 0.030 |
Why?
|
| Follow-Up Studies | 2 | 2008 | 2088 | 0.030 |
Why?
|
| Activities of Daily Living | 1 | 2013 | 230 | 0.030 |
Why?
|
| Iatrogenic Disease | 1 | 2010 | 13 | 0.030 |
Why?
|
| African Americans | 1 | 2019 | 1571 | 0.030 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2010 | 57 | 0.030 |
Why?
|
| Substance-Related Disorders | 1 | 2010 | 94 | 0.020 |
Why?
|
| Severity of Illness Index | 1 | 2013 | 883 | 0.020 |
Why?
|
| Injections, Epidural | 1 | 2009 | 6 | 0.020 |
Why?
|
| Lumbosacral Region | 1 | 2009 | 7 | 0.020 |
Why?
|
| Freund's Adjuvant | 1 | 2007 | 2 | 0.020 |
Why?
|
| Guanosine 5'-O-(3-Thiotriphosphate) | 1 | 2007 | 24 | 0.020 |
Why?
|
| Cell Membrane | 1 | 2007 | 97 | 0.020 |
Why?
|
| Weight-Bearing | 1 | 2007 | 37 | 0.020 |
Why?
|
| Medical Records | 1 | 2007 | 67 | 0.020 |
Why?
|
| Radiography | 1 | 2007 | 295 | 0.020 |
Why?
|
| Double-Blind Method | 1 | 2007 | 519 | 0.020 |
Why?
|
| Databases as Topic | 1 | 2004 | 24 | 0.020 |
Why?
|
| Sampling Studies | 1 | 2004 | 40 | 0.020 |
Why?
|
| Pneumonia | 1 | 2004 | 60 | 0.020 |
Why?
|
| Peripheral Nerves | 1 | 2004 | 54 | 0.020 |
Why?
|
| Odds Ratio | 1 | 2004 | 463 | 0.020 |
Why?
|
| Synaptic Transmission | 1 | 2004 | 114 | 0.020 |
Why?
|
| Multivariate Analysis | 1 | 2004 | 661 | 0.010 |
Why?
|
| Prognosis | 1 | 2007 | 1374 | 0.010 |
Why?
|
| Intracellular Fluid | 1 | 2001 | 2 | 0.010 |
Why?
|
| Receptors, CCR4 | 1 | 2001 | 2 | 0.010 |
Why?
|
| Receptors, CXCR4 | 1 | 2001 | 11 | 0.010 |
Why?
|
| Receptors, Chemokine | 1 | 2001 | 9 | 0.010 |
Why?
|
| Bradykinin | 1 | 2001 | 24 | 0.010 |
Why?
|
| Substance P | 1 | 2001 | 22 | 0.010 |
Why?
|
| Adenosine Triphosphate | 1 | 2001 | 49 | 0.010 |
Why?
|
| Capsaicin | 1 | 2001 | 29 | 0.010 |
Why?
|
| Tail | 1 | 2001 | 7 | 0.010 |
Why?
|
| Fluorescent Dyes | 1 | 2001 | 44 | 0.010 |
Why?
|
| Excitatory Postsynaptic Potentials | 1 | 2001 | 33 | 0.010 |
Why?
|
| Hot Temperature | 1 | 2001 | 74 | 0.010 |
Why?
|
| Neurons, Afferent | 1 | 2001 | 54 | 0.010 |
Why?
|
| Yohimbine | 1 | 1999 | 4 | 0.010 |
Why?
|
| Dexmedetomidine | 1 | 1999 | 9 | 0.010 |
Why?
|
| Adrenergic alpha-Agonists | 1 | 1999 | 35 | 0.010 |
Why?
|
| Anesthesia, Spinal | 1 | 1999 | 23 | 0.010 |
Why?
|
| RNA, Messenger | 1 | 2001 | 530 | 0.010 |
Why?
|
| Cells, Cultured | 1 | 2001 | 790 | 0.010 |
Why?
|